New Psoriasis Injections: Options, Benefits, and Safety
What 'new psoriasis injection' means
'New psoriasis injection' does not identify one specific medicine. The phrase may refer to a recently approved biologic, a drug with a newly expanded approved use, or an injectable treatment that has only recently been offered to a particular patient.
For moderate-to-severe plaque psoriasis in the United States, examples include risankizumab, guselkumab, and bimekizumab. These are prescription biologics that act on selected immune pathways involved in psoriasis. Their approved age groups, dosing schedules, safety information, and indications differ.
These medicines are not the same as a corticosteroid injection placed directly into one isolated lesion. Biologic injections are systemic treatments, meaning they are intended to affect the disease more broadly through the immune system. They are generally considered for defined patient populations rather than automatically for anyone with psoriasis.
The word 'new' also does not establish that one product is universally newest, safest, fastest, or most effective. A dermatologist considers the specific diagnosis, the approved population for the medicine, previous treatment, other health conditions, and practical issues such as administration and access.
Who may be considered for injectable treatment
The biologics discussed here are approved in the United States for defined groups of people with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Risankizumab is indicated for adults and children aged 6 years and older in that setting. The cited guselkumab and bimekizumab indications are for adults.
This does not mean that every person with psoriasis needs an injectable treatment. Psoriasis varies in extent, location, severity, and effect on daily life. A dermatologist may consider the overall disease burden, difficult-to-treat areas, quality-of-life impact, previous therapies, and other health conditions when discussing systemic options. The treatment's approved population must also match the patient's age and diagnosis.
Plaque psoriasis is not the same as psoriatic arthritis or another psoriasis type. A product's approval for plaque psoriasis should not automatically be interpreted as approval for psoriatic arthritis, another form of psoriasis, or every age group. Joint symptoms should be discussed separately because they may affect which specialist assessments or treatment considerations are needed.
Eligibility is therefore a clinical decision rather than a judgment based only on the presence of psoriasis. The dermatologist can explain whether an injectable biologic fits the diagnosis and treatment history, and whether the particular product is approved for that patient's situation.
Newer biologics and how they differ
Risankizumab and guselkumab inhibit the interleukin-23, or IL-23, pathway. Bimekizumab inhibits IL-17A and IL-17F. These targets describe how the medicines act on immune signaling, but the mechanism alone does not establish which drug is best for an individual.
Their cited U.S. plaque-psoriasis populations also differ. Risankizumab is indicated for adults and children aged 6 years and older who have moderate-to-severe plaque psoriasis and are candidates for systemic therapy or phototherapy. The cited guselkumab and bimekizumab indications are for adults in that setting. Pediatric use should not be inferred from an adult indication.
The adult plaque-psoriasis schedules supplied for the first two products are different. Risankizumab is given by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter. Guselkumab is given at weeks 0 and 4 and every 8 weeks thereafter. Bimekizumab has its own product-specific dosing pattern, which should be confirmed from the prescribing information and with the dermatologist rather than inferred from another biologic's schedule.
Other factors can matter as well, including the safety profile, coexisting diseases, administration device, monitoring needs, dosing preference, and access. The products should not be treated as interchangeable, and their milligram strengths or injection intervals should not be used to compare potency.
New Psoriasis Injections: Knowledge Check
How psoriasis injections are given
These biologics are administered under the skin, a method called subcutaneous injection. Many biologic regimens begin with initial doses that are closer together, followed by maintenance doses at longer intervals. The exact pattern depends on the product, the indication, and sometimes the patient's age or weight.
For adult plaque psoriasis, risankizumab is administered as a 150 mg subcutaneous dose at week 0, week 4, and every 12 weeks afterward. Pediatric risankizumab dosing is weight-based and must follow the prescribing information; the adult schedule should not be applied to a child.
For adult plaque psoriasis, guselkumab is administered as a 100 mg subcutaneous injection at weeks 0 and 4 and every 8 weeks afterward. A patient or caregiver should use home administration only after a healthcare professional determines that it is appropriate and provides training.
The device, injection volume, preparation, storage, and administration instructions are product-specific. A patient should follow the instructions for the prescribed product rather than use a schedule or technique from another biologic. The dermatologist or treatment team can explain whether injections will be given in a healthcare setting or at home, how training works, and what to do if an administration problem occurs.
What results patients may expect
Clinical trials commonly assess psoriasis improvement by measuring changes in disease severity and the proportion of participants who reach a high level of improvement or very clear skin. These endpoints help show how a treatment performed in a defined study population, but they cannot predict exactly what will happen for one patient.
In two cited clinical studies of adults with moderate-to-severe plaque psoriasis, at least 7 in 10 participants treated with guselkumab achieved at least a 90% improvement in the Psoriasis Area and Severity Index at week 16. This was a randomized-trial result for the studied population and timeframe, not a guarantee for an individual patient.
The degree and timing of response can vary. A trial result also does not prove that one injection is superior to another unless the products have been compared in an appropriate study. Differences in study design, participants, treatment history, and outcome definitions can make direct comparisons unreliable.
Response should be reviewed with the prescribing dermatologist using the goals set for that patient. The clinician can assess skin improvement, remaining disease, tolerability, and whether the treatment plan remains appropriate instead of applying a universal deadline or personal expectation.
Side effects, screening, and precautions
Infection risk is an important discussion before treatment, but warnings are not identical across all biologics. SKYRIZI and TREMFYA labeling calls for evaluation for infection and tuberculosis before treatment. BIMZELX labeling warns about serious infections, including tuberculosis, and requires condition-appropriate assessment and monitoring by the prescriber.
SKYRIZI can increase infection risk, and treatment should not begin during a clinically important active infection until it resolves or is adequately treated. Its listed common adverse reactions in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection-site reactions, and fungal skin infections. TREMFYA lists respiratory tract infections among common adverse reactions and also includes warnings about serious allergic reactions and liver problems.
BIMZELX has product-specific warnings about suicidal thoughts and behavior, elevated liver enzymes or liver injury, and new or worsening inflammatory bowel disease. These warnings should not automatically be transferred to every biologic. They are topics for assessment and monitoring with the prescribing clinician.
Serious allergic reactions are possible with SKYRIZI and TREMFYA. Facial, mouth, tongue, or throat swelling; trouble breathing; throat or chest tightness; faintness; hives; or itching require stopping the product and obtaining emergency medical help as directed by the product labeling.
Patients using SKYRIZI should avoid live vaccines during treatment. Vaccine planning should be discussed before starting therapy because vaccine precautions can be product-specific. Pregnancy or breastfeeding plans also belong in the treatment discussion. The supplied labeling states that it is not known whether SKYRIZI or BIMZELX can harm an unborn baby or whether either passes into human breast milk, so these questions should not be resolved by assuming safety or harm.
Choosing an injection with a dermatologist
Choosing a biologic involves more than comparing immune targets or injection intervals. The dermatologist may consider the confirmed diagnosis, disease severity and locations, age, previous treatment, other diseases, infection history, pregnancy or breastfeeding plans, monitoring needs, dosing preference, and access to the prescribed product.
Useful questions include:
- What type of psoriasis is being treated, and is the product approved for my age and condition?
- What improvement is a realistic treatment goal?
- What is the dosing schedule, and will injections be given in the office or at home?
- If home administration is appropriate, who needs training?
- Which infection and tuberculosis assessments are needed before treatment?
- Should vaccines be reviewed before starting, and are any vaccine precautions product-specific?
- Which adverse effects should prompt a call to the treatment team or emergency help?
- What monitoring is needed, and when will the response be reviewed?
- How might pregnancy or breastfeeding plans affect the discussion?
- What access, coverage, or supply issues could affect treatment continuity?
The dermatologist can compare the options without treating them as interchangeable. A treatment should not be started, stopped, delayed, or switched solely because of a general comparison article. Those decisions should be made with the prescriber using the product's instructions and the patient's medical circumstances.
'New psoriasis injection' does not identify one specific medicine; it may refer to a recently approved biologic, a newly expanded approved use, or a treatment recently offered to a patient. In the U.S., examples for moderate-to-severe plaque psoriasis include risankizumab, guselkumab, and bimekizumab. These are systemic prescription biologics, not corticosteroid injections into one lesion, and they are generally considered for patients who are candidates for systemic therapy or phototherapy.
The options differ in approved age groups, immune targets, dosing schedules, safety information, and practical factors. Risankizumab is indicated for adults and children 6 years and older; the cited guselkumab and bimekizumab indications are for adults. Trial results can show improvement in a studied population, but they do not predict an individual response or prove that one product is superior unless an appropriate comparison exists.
Before starting, a dermatologist should review diagnosis, severity, previous treatments, other health conditions, infection and tuberculosis evaluation needs, product-specific warnings, vaccine plans, pregnancy or breastfeeding plans, and access. Safety information for some products is not known for an unborn baby or transfer into breast milk. Serious allergic symptoms such as swelling of the face, mouth, tongue, or throat, trouble breathing, throat or chest tightness, faintness, hives, or itching require stopping the product and obtaining emergency medical help as directed by labeling. Patients should not start, stop, delay, or switch biologics based on a general article; decisions should be made with the prescriber using the specific product's instructions and the patient's medical situation.
For a child, an injectable biologic is not automatic. The discussed products are for defined groups with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the U.S., risankizumab is indicated for adults and children 6 years and older in that setting, while the cited guselkumab and bimekizumab indications are for adults; pediatric use should not be inferred from an adult indication.
These injections are given under the skin. Risankizumab adult dosing should not be applied to a child; pediatric risankizumab dosing is weight-based and must follow the prescribing information. The medicines also differ by immune target, schedule, safety profile, administration device, and monitoring needs, so they should not be treated as interchangeable.
Before treatment, the dermatologist should confirm that the diagnosis, age, severity, and treatment history fit the specific product, and review product-specific safety requirements such as infection and tuberculosis evaluation, monitoring, and warning signs. Vaccine planning should be discussed before starting because precautions can be product-specific, and patients using the product labeled SKYRIZI should avoid live vaccines during treatment. Serious allergic symptoms such as swelling of the face, mouth, tongue, or throat, trouble breathing, throat or chest tightness, faintness, hives, or itching require stopping the product and emergency medical help as directed by labeling.
'New psoriasis injection' does not identify one specific medicine; it may refer to a recently approved biologic, a newly expanded approved use, or a treatment recently offered to a patient. For moderate-to-severe plaque psoriasis in the U.S., examples include risankizumab, guselkumab, and bimekizumab. These are systemic prescription biologics, not corticosteroid injections into one lesion, and they are considered for adults who are candidates for systemic therapy or phototherapy.
For adults, eligibility depends on diagnosis, severity, prior treatment, other health conditions, and the specific product's approved population. Risankizumab is indicated for adults and children 6 years and older, while the cited guselkumab and bimekizumab indications are for adults. The biologics are given under the skin with product-specific schedules, and they differ by immune target, safety profile, administration, and monitoring; trial results do not guarantee an individual response or prove that one product is better than another without an appropriate comparison.
Before starting, an adult patient should review infection and tuberculosis evaluation needs, product-specific warnings, vaccine plans, access, and pregnancy or breastfeeding plans with a dermatologist, because some pregnancy and breastfeeding safety information is not known. Serious allergic symptoms such as swelling of the face, mouth, tongue, or throat, trouble breathing, throat or chest tightness, faintness, hives, or itching require stopping the product and emergency medical help as directed by labeling. Treatment should not be started, stopped, delayed, or switched based only on a general article.
Publishing organization: American Academy of Dermatology
Publishing organization: National Institute for Health and Care Excellence
Publishing organization: American Academy of Dermatology and National Psoriasis Foundation
Questions and comments
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.